ROBOKINETICS

ROBOKINETICS: Democratising State-of-the-Art Neurorehabilitation

The Challenge

Acquired Brain Injury (ABI) affects millions of individuals worldwide, often resulting in severe upper-limb motor impairment. Whilst isokinetic dynamometry is recognised as the gold standard for objective neuromuscular assessment and strengthening, its clinical adoption remains significantly constrained. Existing systems are prohibitively expensive, ergonomically complex, and require extensive setup times. Consequently, this high-end therapy is currently restricted to elite sports medicine and specialised research facilities, leaving the vast majority of stroke and trauma patients without access to the most effective recovery tools.

The Solution

RoboKinetics has developed a bimanual, 6-degree-of-freedom (6-DoF) DeepTech robotic platform that, for the first time, makes personalised isokinetic therapy viable for mainstream neurological rehabilitation. Our patent-protected technology utilises a ground-breaking force-control algorithm based on 'Learning from Demonstration' (LfD). This allows physiotherapists to program complex, multi-joint therapeutic protocols in seconds rather than hours; the system intuitively adapts to the patient’s biomechanics, rather than forcing the patient to adapt to the machine.

Value Proposition

• For Healthcare Providers: We significantly reduce operational overheads by optimising clinician time and increasing patient throughput. Our solution enhances diagnostic precision and shortens overall treatment cycles.

• For Clinical Professionals: We provide a high-precision, ergonomic tool that alleviates the physical and cognitive burden of manual therapy, enabling the delivery of data-driven, highly customised rehabilitation protocols.

• For Patients: We transform the recovery journey into an engaging, high-intensity experience through immersive gamification, significantly accelerating the restoration of functional motor skills and autonomy.

Traction and Current Maturity

• Technological Readiness: The technology is currently at TRL 5, with a functional prototype validated in relevant environments. We have a defined roadmap to reach TRL 6 by late 2026.

• Clinical Validation: Clinical trials are currently underway with tier-one healthcare partners, including ASEPEYO (Coslada and Sant Cugat). Further agreements for multi-centric validation are in place with Mutua Terrassa and Los Madroños Hospital.

• Leadership and Ecosystem: The founding team is led by Professor Alberto Jardón (UC3M), a renowned expert in assistive robotics and technology transfer. The project is backed by the Universidad Carlos III de Madrid and mentored by the SECOT network.

Strategic Outlook

We are finishing the process of incorporating as a university spin-off and are actively seeking seed-stage investment to execute our commercialisation strategy. Projected funding will be allocated towards the industrialisation of the prototype, securing CE Marking (MDR compliance), and scaling our multidisciplinary team to bring this transformative Physical AI solution to the global healthcare market.